Novartis Seeks Approval for Gleevec in Four Rare Cancers

Univariate and multivariate analyses showed no significant association between statin use and grade 3 or higher toxicities in patients with CLL or SLL.

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Results from the phase 3 HD21 trial showed that brentuximab vedotin plus chemotherapy was superior to alternative treatments in Hodgkin lymphoma.

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.

Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.

Findings from the phase 1/2 LUPER trial support further assessment of lurbinectedin plus pembrolizumab in relapsed small cell lung cancer.